Tuesday, October 10, 2023 1:40:57 PM
Should Investors Be Buying Context Therapeutics (CNTX)?
(Take a look at CONTEXT Therapeutics) CTIM-76 a CLDN6 antagonist that's in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This selective binding allows CTIM-76 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months. The upcoming Society for Immunotherapy of Cancer meeting may alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize CTIM-76 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trials start showing their results be prepared to pony up for shares. There is now an opportunity to invest in CNTX before the bulk of investors come up to speed concerning the potential market value of a pending CTIM-76 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain shareholder excitement as well. Currently they are on the back burner due to prioritization.
Onapristine is one example of an iron in the fire even if it seems to be on hold for now.
As stated by Context Therapeutics they will "explore strategic options for Onapristine-XR." This leaves the possibility of a joint venture concerning Onapristine or sale of Onapristine outright. Due to elevated liver function tests identified in three patients, including in one patient who discontinued treatment, although NONE of the elevated LFTs were considered serious adverse events. The Company determined that significant incremental program costs and delays were likely to be required. Context is a small entity. Cost is the reason the Oath trial is on hold not a failure.
Investors should look up the Onapristine ER trial (Oath) in the Journal of Clinical Oncology.
Why the focus is on CTIM-76 vs Onapristine even though Onapristine has value? The company see's a better path.
It's been found that CTIM-76 is more specific at binding to the desired target CLDN6 than Amgen's candidate AMG 794 Therefore it's possible CTIM-76 gets a collaboration offer or buyout offer that's large. Amgen knows it & here's why. CTIM-76 is found to be approximately 28 times more potent than a competing approach utilizing a bispecific T-cell engager (BITE) format. Don't overlook; Astellas acquired Ganymed & gains access to mAbs targeting CLDN6 (IMAB027) & CLDN18.2 (IMAB362)... CTIM-76 is thought to have more value in treating cancers.
Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that the forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Like other biotech stocks, share value tends to get heated early when showing potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different; it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened.
Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to break out and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beatdown has occurred and when the facts on the ground for that investment have not changed. If you have invested that way you have better odds at picking a winner.
Concerning the science, CLDN6 differs from other claudins in that it's present in a mothers womb during a baby's development. After development CLDN6 is turned off. Cancer turns back on this claudin 6 to grow. CTIM-76 in development by CONTEXT Therapeutics attacks the turned on CLDN6. CTIM-76 is very specific at targeting CLND6. Other claudins exist that are needed in the body and targeting them could be harmful such as claudin 9 that is needed for hearing.
This isn't anything other than my own research and investors must do their own before making a wise decision.
Recent CNTX News
- Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76 • GlobeNewswire Inc. • 05/02/2024 11:31:53 AM
- Context Therapeutics Announces $100 Million Private Placement • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers • GlobeNewswire Inc. • 04/01/2024 11:30:00 AM
- Context Therapeutics Reports Full Year 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/21/2024 11:43:24 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 12:30:51 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/07/2024 09:24:50 PM
- Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results • GlobeNewswire Inc. • 11/09/2023 09:15:51 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:04:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2023 01:04:29 PM
- Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76 • GlobeNewswire Inc. • 10/31/2023 01:00:00 PM
- Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting • GlobeNewswire Inc. • 09/27/2023 01:00:00 PM
- Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results • GlobeNewswire Inc. • 08/09/2023 08:10:56 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:04:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2023 12:11:05 PM
- Context Therapeutics to Participate in Two August 2023 Investor Conferences • GlobeNewswire Inc. • 08/01/2023 11:30:00 AM
- Context Therapeutics Reports First Quarter 2023 Operating and Financial Results • GlobeNewswire Inc. • 05/10/2023 08:39:59 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM